Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I-II irinotecan for refractory pediatric solid tumors (CPT-PED-05)
jRCT1091220004Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in pediatric solid tumors, sponsored by Children's Oncology Group. Primary endpoints: Dose-limiting toxicity (DLT) in Phase I, Response rate (overall, including Phase II patients) in Phase I and 1 more. Started Jan 2006; status: completed.
02
Drugs
irinotecan
03
Conditions
pediatric solid tumors
Beyond the preview
Go deeper on jRCT1091220004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1091220004.